News
Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...
A recent survey revealed that over 1 in 10 Americans have used a GLP-1 drug for weight loss.Survey results indicated that up ...
Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...
Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...
Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...
FRIDAY, Aug. 8, 2025 (HealthDay News) — A new weight loss pill made by Eli Lilly helped people lose a significant amount of ...
Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...
GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...
People enrolled in the military health care benefits program Tricare for Life no longer will be eligible for coverage of ...
In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.
In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results